Description

Zoltrate 10 mg (Zolpidem Tartrate) Tablets

Zoltrate 10 mg is a non-benzodiazepine sedative-hypnotic formulation of the imidazopyridine class containing zolpidem tartrate. It acts as a preferential, high-affinity positive allosteric modulator at the $\alpha_1$-subunit-containing $\text{GABA}_A$ receptor subtype ($\text{BZ}_1$ receptor) in the central nervous system. This targeted binding amplifies gamma-aminobutyric acid ($\text{GABA}$)-mediated chloride conduction, rapidly facilitating sleep initiation and preserving physiological sleep architecture with minimal muscle-relaxant or anticonvulsant properties at therapeutic dosages.

Product Overview

Primary Indications

Zoltrate 10 mg is prescribed under qualified clinical supervision for:

• Short-Term Treatment of Insomnia: Specifically indicated for individuals experiencing severe sleep-onset insomnia characterized by difficulty falling asleep.

• Transient Sleep Disturbance: Temporary, acute management of situational sleep disruption where daytime functioning is substantially impaired.

Key Information & Precautions

• Dosage & Sex-Differentiated Administration:

  • Clinical guidelines and regulatory warnings establish differential dosing based on clearance rates: the standard recommended initial dose for adult females is 5 mg (due to slower drug elimination), whereas adult males may be initiated on 5 mg or 10 mg.

  • The 10 mg tablet should only be administered if lower doses prove ineffective and only when the patient has a planned full night’s sleep (at least 7 to 8 hours) remaining before awakening.

  • Must be taken immediately before bedtime on an empty stomach; food ingestion delays absorption and significantly reduces onset speed.

• Boxed Warning — Complex Sleep Behaviors: Zolpidem carries a black box warning for serious, potentially fatal complex sleep behaviors. These include sleepwalking, sleep-driving, preparing food, making phone calls, and other activities while not fully awake. The medication must be discontinued immediately if a patient reports any complex sleep event.

• Next-Day Residual Impairment: Higher blood levels the following morning can impair psychomotor skills, alertness, and driving capabilities. Patients should be warned against driving or undertaking safety-critical tasks if less than 8 hours have elapsed post-dose.

• Dependence, Abuse, and Tolerance: Although structurally distinct from classic benzodiazepines, zolpidem carries a definite risk of psychological dependence, physical addiction, tolerance, and misuse. Therapy duration should be restricted to the shortest period necessary (generally not exceeding 2 to 4 weeks).

• Rebound Insomnia & Withdrawal: Abrupt cessation following consecutive nightly use can cause transient rebound insomnia and withdrawal signs (e.g., anxiety, tremors, abdominal cramps). Gradual discontinuation is advised for patients maintained on regular dosing.

• Boxed Warning — Concomitant Depressants: Co-administration with opioids, alcohol, benzodiazepines, or other central nervous system depressants dramatically compounds respiratory depression, profound sedation, coma, and overdose risk.